UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNI MAINZ has a total of 12 patent applications. Its first patent ever was published in 2010. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Argentina. Its main competitors in its focus markets pharmaceuticals, biotechnology and medical technology are GRIFOLS THERAPEUTICS INC, POWDERJECT RES LTD and MYOCARDIAL THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | Argentina | 1 | |
#4 | Germany | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Medical technology | |
#4 | Measurement | |
#5 | Organic fine chemistry | |
#6 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Mann Wolf | 2 |
#2 | Fetz Verena | 2 |
#3 | Seidmann Larissa | 2 |
#4 | Tchirikov Michael | 2 |
#5 | Stauber Roland | 2 |
#6 | Knauer Shirley K | 2 |
#7 | Kirkpatrick Charles James | 2 |
#8 | Koslowski Michael | 1 |
#9 | Xue Shao-An | 1 |
#10 | Florin Luise | 1 |
Publication | Filing date | Title |
---|---|---|
EP2674166A1 | Use of erythropoietin (EPO) for the local treatment of cancer treatment-associated osteo-necrosis of the jaw | |
WO2012127063A1 | SINGLE CHAIN ANTIGEN RECOGNIZING CONSTRUCTS (scARCs) STABILIZED BY THE INTRODUCTION OF NOVEL DISULFIDE BONDS | |
EP2548970A1 | Method for the early diagnosis of clinically latent placental insufficiency in placental dysmaturity | |
EP2484765A1 | Cell transfection under rab37 deficiency or inhibition | |
EP2431364A1 | Nuclear export inhibitors | |
DE102010023438A1 | Balloon catheter system for draining fluids from hollow organs, body cavities or cysts and / or for supplying medication | |
EP2392327A1 | Use of orlistat for the anti-parasitic treatment of a parasitic disease |